×
0 0 0 0 0 0 0 0.00351906158357768
Stockreport

Is bluebird bio One Step Closer to Its First Commercial Drug? [The Motley Fool]

bluebird bio, Inc (BLUE)  More Company Research Source: The Motley Fool
Last bluebird bio, inc earnings: 8/2 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.bluebirdbio.com/investor-overview
PDF Interim results for one of its lead gene therapies could suggest an approval in the future Beta thalassemia patients endure a lifetime of blood transfusions that can cause iron overload and life-threatening organ damage, but a new gene therapy developed by bluebird bio ( NASDAQ:BLUE ) may be about to change that. On Thursday, bluebird bio unveiled intriguing interim results from trials evaluating its beta thalassemia therapy, LentiGlobin, and so far, those results suggest that LentiGlobin could significantly reduce the need for blood transfusions. If the data still is positive when these trials finish, bluebird bio plans to file for European Union approval of LentiGlobin by the end of 2018, and that could mean bluebird bio's about to make the leap from clinical-stage to commercial-stage biotech. IMAGE SOURCE: GETTY IMAGES. What is beta thalassemia? Worldwide, roughly 60,000 children are born with beta thalassemia every year, including 1,500 per year in the [Read more]

IMPACT SNAPSHOT EVENT TIME: BLUE
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BLUE alerts
from News Quantified
Opt-in for
BLUE alerts

from News Quantified
Opt-in for
BLUE alerts

from News Quantified